Vaxxel is an Innovative viral live-attenuated platform for intranasal vaccine candidates preventing against pneumovirus infections
Vaxxel has raised $1.3M in total funding. The most recent round was Seed. The last funding was announced in March 2022.
Vaxxel's investors include Bpifrance, Femmes Business Angels, Angels Santé.
Vaxxel is headquartered in Villeurbanne, France.
Vaxxel is an Innovative viral live-attenuated platform for intranasal vaccine candidates preventing against pneumovirus infections
Vaxxel is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Vaxxel — Funding & Investors." VCBacked, March 18, 2022, https://www.vcbacked.co/company/vaxxel. Accessed August 15, 2026.
VCBacked. (2022). Vaxxel — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/vaxxel
{{cite web |title=Vaxxel — Funding & Investors |url=https://www.vcbacked.co/company/vaxxel |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated